Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Nano announced that Chief Executive Officer Vuong Trieu will present the Deciparticle™ nanomedicine platform at the BIO International Convention 2026 in San Diego, highlighting the development of ultra-small nanomedicine formulations designed to enable intravenous administration of highly water-insoluble therapeutics. The Deciparticle™ platform utilizes proprietary amphiphilic polymer systems capable of forming sub-20 nanometer particles for oncology and other therapeutic applications.
The companies plan to showcase development progress across multiple Deciparticle™ programs, including Sapu006, a polysorbate-free intravenous docetaxel formulation moving into Phase 1b clinical evaluation, and Sapu003, an intravenous everolimus nanomedicine program currently in a global Phase 1b clinical trial. The presentation will also highlight the integration of artificial intelligence and knowledge-organization technologies into formulation development and translational oncology workflows through the PDAOAI™ platform. To view the full press release, visit https://ibn.fm/RUG7m.
The Deciparticle™ platform addresses a key challenge in drug development: many potent therapeutics are highly water-insoluble, limiting their clinical use. By forming particles smaller than 20 nanometers, the platform enables intravenous delivery of compounds that previously required toxic solubilizers or could not be administered systemically. Sapu006, a docetaxel formulation without polysorbate 80, aims to eliminate hypersensitivity reactions associated with current Taxotere® formulations. Sapu003 seeks to repurpose everolimus, an oral mTOR inhibitor, as an intravenous nanomedicine for broader oncology indications.
Beyond the nanomedicine programs, Oncotelic is leveraging its AI-enabled PDAOAI platform to accelerate formulation development and biomarker discovery. The platform integrates knowledge organization and data analysis to optimize nanoparticle design and predict clinical outcomes. This approach represents a convergence of nanotechnology and artificial intelligence, potentially reducing development timelines and costs.
The announcement underscores Oncotelic's broader strategy under CEO Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. The company also owns a 45% interest in GMP Bio, a joint venture advancing complementary therapeutic candidates. For more information about Oncotelic, visit https://ibn.fm/OTLC.
The BIO International Convention is one of the largest biotechnology industry events globally, attracting over 15,000 attendees. Presentation at this venue provides significant visibility for the Deciparticle™ platform and may attract potential partners or investors. The ability to deliver water-insoluble drugs intravenously could expand treatment options for cancer patients and improve safety profiles, making this a notable development in nanomedicine.
